Rezivertinib (BPI-7711)

Chemical Structure : Rezivertinib

CAS No.: 1835667-12-3

加入收藏

货号: PC-38343Not For Human Use, Lab Use Only.

Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance.

规格	价格	库存
5 mg	￥1980	In stock
10 mg	￥2980	In stock
25 mg	￥4980	In stock
50 mg		Get quote
100 mg		Get quote

获取报价单

* 请选择数量再加入购物车

or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

生物&药学活性

Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance.
Rezivertinib (BPI-7711) specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells.
Rezivertinib (BPI-7711) shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR.

物理化学性质&存储条件

分子量	486.576
分子式	C27H30N6O3
外观性状	Solid
CAS No.
储存条件	固体粉末 -20°C 12 个月; 4°C 6 个月	配置液 -80°C 6 个月; -20°C 6 个月
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	N-[2-[2-(dimethylamino)ethoxy]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide

参考文献

1. Yuankai Shi, et al. J Thorac Oncol. 2022 Feb 15;S1556-0864(22)00084-3.

2. Nagasaka M, et al. J Thorac Oncol. 2021 May;16(5):740-763.